Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) Equity Average (2016 - 2025)

Historic Equity Average for Ptc Therapeutics (PTCT) over the last 13 years, with Q3 2025 value amounting to -$181.2 million.

  • Ptc Therapeutics' Equity Average rose 8219.23% to -$181.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$181.2 million, marking a year-over-year increase of 8219.23%. This contributed to the annual value of -$958.3 million for FY2024, which is 6442.68% down from last year.
  • As of Q3 2025, Ptc Therapeutics' Equity Average stood at -$181.2 million, which was up 8219.23% from -$196.2 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Equity Average registered a high of $387.3 million during Q1 2021, and its lowest value of -$1.1 billion during Q4 2024.
  • For the 5-year period, Ptc Therapeutics' Equity Average averaged around -$370.2 million, with its median value being -$287.0 million (2022).
  • As far as peak fluctuations go, Ptc Therapeutics' Equity Average plummeted by 80264.74% in 2023, and later soared by 8219.23% in 2025.
  • Ptc Therapeutics' Equity Average (Quarter) stood at $53.2 million in 2021, then crashed by 639.65% to -$287.0 million in 2022, then crashed by 159.48% to -$744.7 million in 2023, then crashed by 44.52% to -$1.1 billion in 2024, then skyrocketed by 83.17% to -$181.2 million in 2025.
  • Its Equity Average stands at -$181.2 million for Q3 2025, versus -$196.2 million for Q2 2025 and -$641.9 million for Q1 2025.